Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Chicago, Illinois

CNS medication trials in Chicago, IL

62 CNS medication studies are recruiting participants at sites in Chicago as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Chicago at a glance

Depression studies recruiting in Chicago

Basic details from each study's public record (the 30 most recently updated of 62). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Rush University
    Registry record
    NCT06793397 · updated
  2. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study sites
    Rush University Medical Center · University of Chicago Medical Center
    Registry record
    NCT07002034 · updated
  3. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Uptown Research Institute
    Registry record
    NCT07592689 · updated
  4. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Ann & Robert H. Lurie Children's Hospital of Chicago
    Registry record
    NCT06372964 · updated
  5. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Northwestern University
    Registry record
    NCT06559306 · updated
  6. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Chicago Research Center
    Registry record
    NCT07573176 · updated
  7. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Charter Research - Chicago
    Registry record
    NCT07775300 · updated
  8. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Chicago, IL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Chicago

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    EmVenio Research Center - Prime Healthcare
    Registry record
    NCT07288567 · updated
  2. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study sites
    Pillar Clinical Research -Chicago · Uptown Research Institute
    Registry record
    NCT07221877 · updated
  3. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    EmVenio Research Center - Prime Healthcare
    Registry record
    NCT07424404 · updated
  4. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

    • Phase 1
    • Ages 18 to 60
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Uptown Research Institute
    Registry record
    NCT07615426 · updated
  5. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Pillar Clinical Research -Chicago
    Registry record
    NCT07686263 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Chicago, IL on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Chicago

  1. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research -Chicago
    Registry record
    NCT07140913 · updated
  2. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research -Chicago
    Registry record
    NCT06929273 · updated
  3. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research -Chicago
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Chicago, IL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Chicago

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    The University of Chicago Medical Center ( Site 0118)
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Illinois Cancer Center ( Site 0044)
    Registry record
    NCT06841354 · updated
  3. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Chicago Medical Center ( Site 5002)
    Registry record
    NCT06952504 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Northwestern University Feinberg School Of Medicine
    Registry record
    NCT07174310 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Northwestern Medical Group, Department of Neurology
    Registry record
    NCT06680830 · updated
  6. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Chicago, IL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Chicago

  1. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study sites
    Rush University Medical Center · University of Chicago
    Registry record
    NCT06846281 · updated
  2. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Chicago, IL on ClinicalTrials.gov.

Epilepsy studies recruiting in Chicago

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07594119 · updated
  2. A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Encoded Therapeutics
    Study site
    Ann & Robert H. Lurie Children's Hospital of Chicago
    Registry record
    NCT05419492 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Chicago, IL on ClinicalTrials.gov.

Migraine studies recruiting in Chicago

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Cedar Crosse Research Center · Chicago Headache Center & Research Institute
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Cedar Crosse Research Center · Chicago Headache Center & Research Institute
    Registry record
    NCT07674654 · updated
  3. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Chicago Headache Center & Research Institute
    Registry record
    NCT04649242 · updated
  4. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Chicago Headache Center & Research Institute
    Registry record
    NCT04743141 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Chicago, IL on ClinicalTrials.gov.

Ask about studies near Chicago

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call